Abstracts tagged "Adalimumab and biosimilars"

Abstract Number: 2446 • 2017 ACR/ARHP Annual Meeting
Minimal and Comparable Radiographic Progression By Disease Activity States in Patients with Rheumatoid Arthritis Who Continued SB5 or Reference Adalimumab and Who Switched to SB5
Michael Weinblatt¹, Asta Baranauskaite², Jeehoon Ghil³, Soo Yeon Cheong³ and Evelyn Hong³, ¹Brigham and Women’s Hospital, Boston, MA, ²Lithuanian University of Health Sciences, Kaunas, Lithuania, ³Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)
Background/Purpose : SB5 is a biologic agent developed as a biosimilar of the reference adalimumab (ADL). One year results including radiographic progression from the phase…
Abstract Number: 2757 • 2015 ACR/ARHP Annual Meeting
Secondary Efficacy Endpoints: Results from a Phase 3 Study Comparing ABP 501 with Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis
Alan K. Matsumoto¹, Karel Pavelka², Warren Rizzo³, Ramesh Gupta⁴, William Shergy⁵, Pawel Heycaj⁶, Nan Zhang⁷ and Primal P. Kaur⁸, ¹Rheumatology, Arthritis & Rheumatism Assoc, Wheaton, MD, ²Charles University, Prague, Czech Republic, ³Advanced Arthritis Care & Research, Scottsdale, AZ, ⁴Private Practice, Rheumatology, Memphis, TN, ⁵RANA Clinical Research Center, Huntsville, AL, ⁶Rheumatology and Clinical Immunology, Poznañ University of Medical Sciences, Poznan, Poland, ⁷Biosimilars, Amgen, Inc., Thousand Oaks, CA, ⁸Amgen, Inc., Thousand Oaks, CA
Background/Purpose: ABP 501 is being developed as a biosimilar candidate to adalimumab (Humira®), a fully human recombinant monoclonal antibody. Evidence from analytical and pharmacokinetic comparisons…
Abstract Number: 1503 • 2014 ACR/ARHP Annual Meeting
Demonstration of Functional Similarity Comparing Adalimumab to Biosimilar Candidate ABP 501
Teresa Born¹, Jyoti Velayudhan², Yuh-fung Chen³, Heather Thomas⁴, Christina Pastula², Gwen Maher³ and Ryan Brown⁴, ¹Biosimilars Process Development, Amgen, Seattle, WA, ²Functional Biocharacterization, Amgen, Seattle, WA, ³Functional Biocharacterization, Amgen, Thousand Oaks, CA, ⁴Inflammation Research, Amgen, Seattle, WA
Background/Purpose: ABP 501 is being developed as a biosimilar to adalimumab, a recombinant monoclonal antibody that binds tumor necrosis factor alpha (TNF) thus inhibiting engagement…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].